Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections.

Abstract

Antibody-based passive immunotherapy has been used effectively in the treatment and prophylaxis of infectious diseases. Outbreaks of emerging viral infections from arthropod-borne viruses (arboviruses) represent a global public health problem due to their rapid spread, urging measures and the treatment of infected individuals to combat them. Preparedness in advances in developing antivirals and relevant epidemiological studies protect us from damage and losses. Immunotherapy based on monoclonal antibodies (mAbs) has been shown to be very specific in combating infectious diseases and various other illnesses. Recent advances in mAb discovery techniques have allowed the development and approval of a wide number of therapeutic mAbs. This review focuses on the technological approaches available to select neutralizing mAbs for emerging arbovirus infections and the next-generation strategies to obtain highly effective and potent mAbs. The characteristics of mAbs developed as prophylactic and therapeutic antiviral agents for dengue, Zika, chikungunya, West Nile and tick-borne encephalitis virus are presented, as well as the protective effect demonstrated in animal model studies.

• Authors: Leonardo F Ormundo, Carolina T Barreto, Lilian R Tsuruta
• Journal: Viruses (Viruses) Vol. 15 Issue 11 (Oct 30 2023) ISSN: 1999-4915 [Electronic] Switzerland
• PMID: 38005854 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal

Topics

• Animals
• Humans
• Antibodies, Monoclonal (therapeutic use)
• Arbovirus Infections (drug therapy, prevention & control)
• Arboviruses
• Virus Diseases (drug therapy)
• Communicable Diseases
• Zika Virus
• Zika Virus Infection (drug therapy)